Strategic Insider Trades and Promising Developments in TriSalus Life Sciences

TriSalus Life Sciences (TLSI:US), a cutting-edge oncology-focused company with a market capitalization of $155.82 million, is transforming cancer treatment through its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) technology. This innovative approach enhances therapy penetration in liver and pancreatic tumors, integrating advanced drug delivery with investigational immunotherapy to overcome tumor-associated immunosuppression.

Strategic Insider Trades Highlight Confidence

In recent months, several key insiders have made significant purchases of NowVertical's subordinate voting shares, signaling strong confidence in the company's future prospects.

Between January 27 and January 30, President and CEO Mary T. Szele and Board Member Sean Edward Murphy acquired 49,582 shares, totaling $259,253. Additionally, CFO James Emmett Young made his initial transaction of 24,000 shares on January 27, amounting to $129,600. 

Financial Growth and Operational Strength

TriSalus recently announced its preliminary Q4 and full-year 2024 financial results. The company reported Q4 revenue of approximately $8.3 million, marking a 44% increase year-over-year. Full-year 2024 revenue reached $29.4 million, reflecting a 59% growth compared to 2023. 

Notably, Q4 operating cash flow improved to ($5.6) million from ($10.8) million in Q3. The company expects to achieve positive full-year EBITDA and positive cash flow in the second half of 2025, reinforcing its financial stability.

Groundbreaking Research on PEDD™ Technology

TriSalus’ recent study, published in the Journal of Vascular and Interventional Radiology, demonstrated that PEDD™ achieved a 227% increase in tumor penetration and a 209% increase in peritumoral delivery compared to traditional methods. This research further validates TriNav® Infusion System’s potential to revolutionize liver tumor treatment.

With strategic insider investments, strong financial momentum, and innovative advancements, TriSalus Life Sciences is well-positioned for continued success in the oncology space.